- ISIN
- US09075P1057
- CUSIP
- 09075P105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 8, 2018
Highlights
- Market Cap
- $28.05M
- Enterprise Value
- $133.59M
- EPS (TTM)
- -$5.21
- Total Revenue (TTM)
- $680.00K
- Gross Profit (TTM)
- $175.00K
- EBITDA (TTM)
- -$61.68M
- Year Range
- $1.01 - $8.08
- Target Price
- $12.00
- ROA (TTM)
- -221.41%
- ROE (TTM)
- 71.38%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BTAI Performance Chart
BioXcel Therapeutics, Inc. (BTAI) is down 25.6% since the beginning of the year. At $1 per share, BTAI is trading 85.3% below its 52-week high of $8. Investors who bought $1,000 worth of BTAI shares 5 years ago would now be looking at an investment worth $2.
Loading charts...
Returns By Period
BioXcel Therapeutics, Inc. (BTAI) has returned -25.62% so far this year and -9.85% over the past 12 months.
BioXcel Therapeutics, Inc.
- 1D
- 0.00%
- 1M
- -0.83%
- YTD
- -25.62%
- 6M
- -36.36%
- 1Y
- -9.85%
- 3Y*
- -84.22%
- 5Y*
- -70.84%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
BTAI Monthly Returns History
Based on dividend-adjusted daily data since Mar 8, 2018, BTAI's average daily return is +0.02%, while the average monthly return is +0.59%. At this rate, an investment would double in approximately 9.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was Aug 2025 with a return of +209.2%, while the worst month was Jun 2023 at -62.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, BTAI closed higher 45% of trading days. The best single day was Aug 4, 2025 with a return of +85.4%, while the worst single day was Jun 29, 2023 at -63.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.62% | 5.03% | -19.76% | -8.21% | -4.88% | 1.71% | -25.62% | ||||||
| 2025 | -12.81% | -58.59% | -6.02% | -8.87% | -36.22% | 53.39% | -27.62% | 209.16% | -36.79% | -19.92% | 9.76% | -28.89% | -73.25% |
| 2024 | 9.15% | -1.24% | -11.32% | -10.64% | -28.17% | -29.28% | -12.50% | -45.09% | -0.81% | 9.31% | -38.66% | -8.58% | -87.33% |
| 2023 | 32.77% | 11.92% | -41.54% | 10.50% | -13.00% | -62.88% | 37.24% | -58.64% | -33.07% | 58.70% | -5.35% | -22.37% | -86.27% |
| 2022 | -16.87% | 8.34% | 14.20% | -37.30% | -10.76% | 12.82% | 16.97% | -11.40% | -13.60% | 6.51% | 31.61% | 29.63% | 5.66% |
| 2021 | 0.26% | 15.74% | -19.49% | -21.29% | -2.77% | -12.02% | -11.94% | 15.08% | 3.06% | -3.99% | -21.31% | -11.34% | -56.00% |
Benchmark Metrics
BioXcel Therapeutics, Inc. has an annualized alpha of -14.09%, beta of 1.48, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 09, 2018.
- This stock participated in 169.88% of S&P 500 Index downside but only -47.14% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -14.09%
- Beta
- 1.48
- R²
- 0.06
- Upside Capture
- -47.14%
- Downside Capture
- 169.88%
Return for Risk
Risk / Return Rank
BTAI ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioXcel Therapeutics, Inc. (BTAI) and compare them to S&P 500 Index.
| BTAI | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.07 | 2.39 | -2.46 |
Sortino ratioReturn per unit of downside risk | 1.09 | 3.25 | -2.16 |
Omega ratioGain probability vs. loss probability | 1.12 | 1.43 | -0.31 |
Calmar ratioReturn relative to maximum drawdown | -0.12 | 3.11 | -3.23 |
Martin ratioReturn relative to average drawdown | -0.15 | 14.38 | -14.54 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioXcel Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioXcel Therapeutics, Inc. was 99.90%, occurring on Apr 13, 2026. The portfolio has not yet recovered.
The current BioXcel Therapeutics, Inc. drawdown is 99.88%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.90%Apr 2026 | 5y 8mo | — | 5y 10moJul 2020 - now |
Rate-hike selloffLate 2018 | -81.45%Dec 2018 | 5mo 18d | 1y 5d | 1y 5moJul 2018 - Dec 2019 |
COVID crash2020 | -64.05%Mar 2020 | 25d | 1mo 26d | 2mo 21dFeb 2020 - May 2020 |
2018 bear market2018 | -36.53%May 2018 | 26d | 20d | 1mo 16dApr 2018 - May 2018 |
2020 bear market2020 | -26.63%Jan 2020 | 3d | 7d | 10dJan 2020 - Jan 2020 |
Drawdown Indicators
| BTAI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.90% | -56.78% | -43.12% |
Max Drawdown (1Y)Largest decline over 1 year | -85.00% | -9.10% | -75.90% |
Max Drawdown (3Y)Largest decline over 3 years | -99.70% | -18.90% | -80.80% |
Max Drawdown (5Y)Largest decline over 5 years | -99.84% | -25.43% | -74.41% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.88% | 0.00% | -99.88% |
Average DrawdownAverage peak-to-trough decline | -63.17% | -10.72% | -52.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.21% | 1.97% | +62.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioXcel Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioXcel Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BTAI relative to other companies in the Biotechnology industry. Currently, BTAI has a P/S ratio of 25.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BTAI
Add BioXcel Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BTAI